Groundbreaking work that Elazer Edelman is doing in endothelium and biomaterials using imaging as endpoint
If you want to know more about CV imaging, follow us and read our articles! @IntJCVImaging#echofirst#yescct#whyCMR
One of the best lectures I have ever attended! Only Elazar Edelman can mix together endothelium, quantum physics, history, philosophy, determinism vs heuristics, through the lens of modernism
Love the reenactment of the famous image of Laennec auscultation! (2nd photo) @DLBHATTMD
One of the best lectures I have ever attended! Only Elazar Edelman can mix together endothelium, quantum physics, history, philosophy, determinism vs heuristics, through the lens of modernism
Love the reenactment of the famous image of Laennec auscultation! (2nd photo) @DLBHATTMD
It is my honor and my privilege to be a Discussant for the Late-Breaking Clinical Trial Session editorializing the SOUL trial
Oral semaglutide ⬇️3P-MACE by 14% in T2DM with CVD and/or CKD. Plus improvement in PAD events too
@DLBHATTMD@dranulala@MountSinaiHeart@IcahnMountSinai
What a great moment to be working in HFpEF specifically and cardiometabolism in general!
Wanna learn how to evaluate HFpEF using imaging? Read our journal @IntJCVImaging#echofirst#yesCCT#whyCMR
Another summit (see what I did here?) in the HFpEF revolution! The dual GLP1/GIP mimetic tirzepatide improves outcomes in HFpEF with obesity!
SUMMIT trial showed 38% ⬇️ in HF outcomes (=time-to-first HFH, oral diuretic intensification and CV death)!! https://t.co/apLuJ4n2X4
What a tour de force by the amazing @PamTaubMD as Visiting Professor at @MountSinaiHear!
She masterfully took us through her journey from cardiometabolism to time-restricted eating to POTS to Long Covid, all with impeccable scientific accumen and humility!
@DLBHATTMD
Wow! An SGLT2i is sold at $47.85!!!! (shipping included) 🥳🍾🎉🤑💸
That is 8% of the going price of empagliflozin or dapagliflozin!!
Caveat: Only indication in T2DM (not HF or CKD)
https://t.co/e17wlZfHM5
@ChristosArgyrop@JonathanDavisHF@AndrewJSauer@hvanspall@dranulala
Proud to present tomorrow the latest evidence at #ADA2023 about SGLT2i and heart failure.
Best panel ever with my friends Darren McGuire (discussing SGLT2i/GLP1RA) and @PamTaubMD (discussing GLP-1RA in CVD), moderated by @gandaom@DLBHATTMD@GoggleDocs
https://t.co/kOM7zQKQNC
Amazing talk about GLP-1RA by the incredibly talented @PamTaubMD!
Loved that she focused on novel fields beyond the "traditional" weight loss effects
#ADA2023
Breaking news: FDA has just approved sotagliflozin (brand name "Inpefa") for Treatment of Heart Failure!!!!
Broad label across full LVEF range (HFpEF&HFrEF), and for patients with or without T2DM
First dual SGLT1/2 inhibitor to be approved in HF
@DLBHATTMD@ChristosArgyrop
I have learnt so many concepts about RV evaluation from thr master himself, the one and only @RyanTedfordMD, in the Grand Rounds at #McMaster organized by @hvanspall
Importance of RV/PA coupling over contractility, of exercise/pharmacological reserve over at-rest evaluation,…
Great use of cardiovascular imaging techniques to demonstrate that empagliflozin reduces MI size!
If you want to learn more about cardiac imaging, read our journal @IntJCVImaging
Great editorial comment about the CLEAR Outcomes trial by the world-renown lipid expert @juanbadimon
As we are an imaging journal, this trial could only be better if it also had imaging endpoints!
#whyCMR#yesCCT#echofirst
Everything you wanted to know about the CLEAR-Outcomes trial, but were afraid to ask.
Read my view on the latest @secardiologia blog entry
LDL, the lower the better, the earlier the better!
https://t.co/dteyF3BRRI
@lipidmir@ResiSec#cardioed#meded@Capijorge1
"EMPULSE: en insuficiencia cardiaca aguda, empagliflozina causa mejoría de la congestión temprana, efectiva y sostenida en el tiempo, que se asocia con beneficio clínico a largo plazo", señala @santosgallegoMD. #BlogSEC@jovenesSEC https://t.co/BjnW6mEiNY
With every passing day I learn that @SantosGallegoMD is an expert on another topic (SGLT2i, Spanish wine, opera, Futbol, tapas, bourbon…the list is endless). @rachkataria and @JonathanDavisHF decided that he is the most interesting man in the world. (#AHA22 edition)